EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer

In non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, 50%–65% of cases acquire resistance after treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) because of an EGFR T790M point mutation and 3%–14% of these cases transformed to small cell lung cancer...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine case reports 2018-01, Vol.24, p.19-21
Main Authors: Sonoda, Tomoaki, Nishikawa, Shingo, Sakakibara, Rie, Saiki, Masafumi, Ariyasu, Ryo, Koyama, Junji, Kitazono, Satoru, Yanagitani, Noriko, Horiike, Atsushi, Ohyanagi, Fumiyoshi, Ninomiya, Hironori, Ishikawa, Yuichi, Nishio, Makoto
Format: Article
Language:English
Subjects:
Case Report
EGFR mutation
NSCLC
Osimertinib
SCLC transformation
T790M
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, 50%–65% of cases acquire resistance after treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) because of an EGFR T790M point mutation and 3%–14% of these cases transformed to small cell lung cancer (SCLC). Generally, the EGFR T790M secondary mutation develops with ongoing ATP competitive inhibition. We present a case of a 76-year-old woman with lung adenocarcinoma harboring an EGFR-L858R mutation who received first-line gefitinib and developed SCLC transformation. She was administered several chemotherapy agents, including a platinum doublet. The primary lesion that showed SCLC transformation had reconverted to adenocarcinoma with EGFR L858R and T790M mutations at the time of a second re-biopsy. Therefore, she was administered osimertinib, which resulted in clinical remission. This case suggested that serial biopsies are necessary even after SCLC transformation.
ISSN:2213-0071
2213-0071
DOI:10.1016/j.rmcr.2018.03.009